secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2024-03-22T23:59:59+00:00
Accession:  0001437749-24-008919
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Pharma acquires U.S. rights to PKU GOLIKE for $2.2M upfront plus milestones and 30% royalty
--------------------------------------------------------------------------------

- Acquired U.S. rights to PKU GOLIKE for $2.2M upfront, up to $2M milestones, and 30% royalty on net sales.
- PKU GOLIKE targets phenylketonuria (PKU) in an estimated $100M U.S. medical formula market.
- Deal expected to be accretive to 2024 earnings; peak sales forecast >$10M annually.
- Also acquired U.S. rights to line extensions for tyrosinemia, homocystinuria (launch 2025/2026) and right of first negotiation for RLF-OD032.
- Product complements Eton's metabolic franchise; promoted by existing sales force targeting metabolic geneticists.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774924008919/0001437749-24-008919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774924008919/eton20240318_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-008919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer